share_log

健康元(600380.SH):JP-1366片获得药物临床试验批准通知书

Health Source (600380.SH): JP-1366 tablets obtained approval notice for drug clinical trials

Gelonghui Finance ·  Feb 22 05:06

On February 22, Ge Longhui Health Yuan (600380.SH) announced that the company's holding subsidiary, Livou Group Livzon Pharmaceutical Research Institute (hereinafter: Lizhu Research Institute), a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” (Notice Number: 2024LP00422) approved and issued by the State Drug Administration and approved JP-1366 tablets to conduct clinical trials.

JP-1366 is an innovative potassium competitive acid blocker (P-CAB) developed by Korea's Onconic Therapeutics Inc. (Onconic) in the early stages. Currently, it has submitted a marketing application in Korea. It has the advantages of fast efficacy, excellent acid suppression effect, long-lasting effects, and few adverse reactions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment